Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...

FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...

Diabetes drugs now represent over 75% of total sales in the metabolic disorders market, up from below 40% ten years ago. The ...

CWA Asset Management Group LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 11.9% in ...

There are now more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...